Compare Stocks: UNCY, SPRY, AVIR, and RLMD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVIR Atea Pharmaceuticals	$4.98 -1.0%	$5.28	$2.87 ▼ $6.45	$403.43M	0.39	289,005 shs	303,226 shs
RLMD Relmada Therapeutics	$3.36 -4.3%	$4.24	$1.80 ▼ $8.00	$374.41M	0.51	1.28 million shs	1.42 million shs
SPRY ARS Pharmaceuticals	$4.05 -3.1%	$5.08	$3.98 ▼ $13.15	$415.69M	0.85	1.47 million shs	1.55 million shs
UNCY Unicycive Therapeutics	$3.73 -7.9%	$4.96	$3.67 ▼ $8.74	$112.81M	1.83	918,363 shs	1.84 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVIR Atea Pharmaceuticals	-0.99%	-1.78%	-6.21%	+2.47%	+60.13%
RLMD Relmada Therapeutics	-4.27%	+2.44%	-25.66%	-45.89%	+66.34%
SPRY ARS Pharmaceuticals	-3.11%	-5.81%	-14.92%	-46.36%	-62.95%
UNCY Unicycive Therapeutics	-7.90%	-11.82%	-29.49%	-25.70%	-16.93%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVIR Atea Pharmaceuticals	$4.98 -1.0%	$5.28	$2.87 ▼ $6.45	$403.43M	0.39	289,005 shs	303,226 shs
RLMD Relmada Therapeutics	$3.36 -4.3%	$4.24	$1.80 ▼ $8.00	$374.41M	0.51	1.28 million shs	1.42 million shs
SPRY ARS Pharmaceuticals	$4.05 -3.1%	$5.08	$3.98 ▼ $13.15	$415.69M	0.85	1.47 million shs	1.55 million shs
UNCY Unicycive Therapeutics	$3.73 -7.9%	$4.96	$3.67 ▼ $8.74	$112.81M	1.83	918,363 shs	1.84 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVIR Atea Pharmaceuticals	-0.99%	-1.78%	-6.21%	+2.47%	+60.13%
RLMD Relmada Therapeutics	-4.27%	+2.44%	-25.66%	-45.89%	+66.34%
SPRY ARS Pharmaceuticals	-3.11%	-5.81%	-14.92%	-46.36%	-62.95%
UNCY Unicycive Therapeutics	-7.90%	-11.82%	-29.49%	-25.70%	-16.93%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVIR Atea Pharmaceuticals	2.33	Hold	$7.00	40.56% Upside
RLMD Relmada Therapeutics	2.75	Moderate Buy	$12.00	257.14% Upside
SPRY ARS Pharmaceuticals	2.50	Moderate Buy	$25.00	517.28% Upside
UNCY Unicycive Therapeutics	2.57	Moderate Buy	$18.25	389.28% Upside

Current Analyst Ratings Breakdown

Latest UNCY, SPRY, AVIR, and RLMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/29/2026	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$15.00 ➝ $13.00
9/14/2026	RLMD Relmada Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/8/2026	SPRY ARS Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$15.00
9/4/2026	UNCY Unicycive Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
8/20/2026	UNCY Unicycive Therapeutics	Benchmark Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Speculative Buy	$13.00 ➝ $15.00
8/19/2026	UNCY Unicycive Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
8/17/2026	SPRY ARS Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	AVIR Atea Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Equal Weight	$6.00 ➝ $7.00
8/13/2026	UNCY Unicycive Therapeutics	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$37.00 ➝ $25.00
8/12/2026	UNCY Unicycive Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$22.00 ➝ $20.00
7/21/2026	UNCY Unicycive Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell

(Data available from 10/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	$3.53 per share	N/A
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	$1.18 per share	N/A
SPRY ARS Pharmaceuticals	$84.28M	4.78	N/A	N/A	$1.16 per share	3.49
UNCY Unicycive Therapeutics	$680K	152.77	N/A	N/A	$1.41 per share	2.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVIR Atea Pharmaceuticals	-$158.35M	-$2.08	N/A	N/A	N/A	N/A	-64.25%	-57.12%	11/11/2026 (Estimated)
RLMD Relmada Therapeutics	-$57.38M	-$0.90	N/A	N/A	N/A	N/A	-47.52%	-43.97%	11/12/2026 (Estimated)
SPRY ARS Pharmaceuticals	-$171.30M	-$2.18	N/A	N/A	N/A	-184.24%	-256.67%	-69.63%	11/9/2026 (Estimated)
UNCY Unicycive Therapeutics	-$26.56M	-$1.75	N/A	1.95	N/A	N/A	-91.50%	-61.47%	11/11/2026 (Estimated)

Latest UNCY, SPRY, AVIR, and RLMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	SPRY ARS Pharmaceuticals	-$0.33	N/A	N/A	N/A	$42.84 million	N/A
8/13/2026	Q2 2026	SPRY ARS Pharmaceuticals	-$0.4777	-$0.63	-$0.1523	-$0.63	$31.32 million	$33.66 million
8/12/2026	Q2 2026	AVIR Atea Pharmaceuticals	-$0.5550	-$0.41	+$0.1450	-$0.41	$33.03 million	N/A
8/12/2026	Q2 2026	UNCY Unicycive Therapeutics	-$0.4710	-$0.06	+$0.4110	-$0.06	$22.22 million	N/A
8/6/2026	Q2 2026	RLMD Relmada Therapeutics	-$0.1995	-$0.11	+$0.0895	-$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVIR Atea Pharmaceuticals	N/A	8.13	8.13
RLMD Relmada Therapeutics	N/A	29.52	29.52
SPRY ARS Pharmaceuticals	13.72	3.48	3.28
UNCY Unicycive Therapeutics	N/A	3.81	3.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVIR Atea Pharmaceuticals	86.67%
RLMD Relmada Therapeutics	45.24%
SPRY ARS Pharmaceuticals	68.16%
UNCY Unicycive Therapeutics	40.42%

Insider Ownership

Company	Insider Ownership
AVIR Atea Pharmaceuticals	21.60%
RLMD Relmada Therapeutics	14.50%
SPRY ARS Pharmaceuticals	33.80%
UNCY Unicycive Therapeutics	6.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVIR Atea Pharmaceuticals	55	80.21 million	62.88 million	Optionable
RLMD Relmada Therapeutics	17	106.67 million	91.20 million	Optionable
SPRY ARS Pharmaceuticals	200	99.45 million	65.83 million	Optionable
UNCY Unicycive Therapeutics	22	27.85 million	26.18 million	Not Optionable

UNCY, SPRY, AVIR, and RLMD Headlines

Recent News About These Companies

Unicycive Deadline: UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit

October 13 at 7:39 PM | prnewswire.com

UNCY Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Unicycive ...

October 13 at 5:31 PM | gazettextra.comG

Kaplan Fox Reminds Investors of the November 2, 2026 Deadline in the Securities Class Action Against Unicycive Therapeutics, Inc. (UNCY)

October 13 at 4:30 PM | newsfilecorp.comN

UNICYCIVE DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

October 13 at 4:12 PM | newsfilecorp.comN

UNCY Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Unicycive Therapeutics Securities Lawsuit - Contact SueWallSt

October 13 at 1:51 PM | globenewswire.com

UNCY INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

October 13 at 12:37 PM | newsfilecorp.comN

Unicycive Therapeutics (UNCY) Loses 21.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

October 13 at 10:36 AM | zacks.com

Kaplan Fox & Kilsheimer LLP Alerts Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors to the Lead Plaintiff Deadline on November 2, 2026

October 13 at 7:26 AM | theglobeandmail.com

UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, ...

October 12 at 9:22 PM | reflector.comR

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

October 12 at 4:07 PM | newsfilecorp.comN

UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class Action - Contact Levi & Korsinsky

October 12 at 1:49 PM | globenewswire.com

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

October 11 at 2:16 PM | newsfilecorp.comN

UNCY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

October 11 at 1:51 PM | newsfilecorp.comN

ROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

October 10, 2026 | newsfilecorp.comN

ROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

October 9, 2026 | newsfilecorp.comN

Kaplan Fox Announces the Lead Plaintiff Deadline of November 2, 2026 in the Securities Class Action Against Unicycive Therapeutics, Inc. (UNCY)

October 9, 2026 | newsfilecorp.comN

UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit

October 8, 2026 | prnewswire.com

Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

October 8, 2026 | globenewswire.com

UNCY Deadline Alert: SueWallSt Reminds Unicycive Therapeutics, Inc. (UNCY) Investors of Securities Class Action Deadline on November 2, 2026

October 8, 2026 | prnewswire.com

Unicycive Therapeutics, Inc. UNCY Investors with Significant Losses Encouraged to Contact Kirby McInerney LLP About Securities Class Action

October 8, 2026 | newsfilecorp.comN

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Stock Rated "Moderate Buy" by Wall Street Analysts

October 2, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

UNCY, SPRY, AVIR, and RLMD Company Descriptions

Atea Pharmaceuticals NASDAQ:AVIR

$4.98 -0.05 (-0.99%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$4.99 +0.00 (+0.10%)

As of 10/13/2026 07:30 PM Eastern

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Relmada Therapeutics NASDAQ:RLMD

$3.36 -0.15 (-4.27%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$3.38 +0.02 (+0.45%)

As of 10/13/2026 07:46 PM Eastern

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

ARS Pharmaceuticals NASDAQ:SPRY

$4.05 -0.13 (-3.11%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$4.05 0.00 (0.00%)

As of 04:02 AM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Unicycive Therapeutics NASDAQ:UNCY

$3.73 -0.32 (-7.90%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$3.78 +0.05 (+1.23%)

As of 04:35 AM Eastern

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest UNCY, SPRY, AVIR, and RLMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest UNCY, SPRY, AVIR, and RLMD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

UNCY, SPRY, AVIR, and RLMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

UNCY, SPRY, AVIR, and RLMD Company Descriptions

Atea Pharmaceuticals NASDAQ:AVIR

Relmada Therapeutics NASDAQ:RLMD

ARS Pharmaceuticals NASDAQ:SPRY

Unicycive Therapeutics NASDAQ:UNCY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest UNCY, SPRY, AVIR, and RLMD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest UNCY, SPRY, AVIR, and RLMD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

UNCY, SPRY, AVIR, and RLMD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

UNCY, SPRY, AVIR, and RLMD Company Descriptions

Atea Pharmaceuticals NASDAQ:AVIR

Relmada Therapeutics NASDAQ:RLMD

ARS Pharmaceuticals NASDAQ:SPRY

Unicycive Therapeutics NASDAQ:UNCY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools